1 Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403-416, doi:10.1056/NEJMoa2035389 (2021).
2 Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med, doi:10.1056/NEJMoa2110345 (2021).
3 Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99-111, doi:10.1016/S0140-6736(20)32661-1 (2021).
4 Marfe, G., Perna, S. & Shukla, A. K. Effectiveness of COVID-19 vaccines and their challenges (Review). Exp Ther Med 22, 1407, doi:10.3892/etm.2021.10843 (2021).
5 Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 384, 2187-2201, doi:10.1056/NEJMoa2101544 (2021).
6 Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671-681, doi:10.1016/S0140-6736(21)00234-8 (2021).
7 Voko, Z. et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect 28, 398-404, doi:10.1016/j.cmi.2021.11.011 (2022).
8 AlQahtani, M. et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. preprint, researchsquare, doi:10.21203/rs.3.rs-828021/v1 (2021).
9 Ryzhikov, A. B. & et.al. Immunogenicity and Protectivity of the Peptide Vaccine against SARS-CoV-2. Annals of the Russian Academy of Medical Sciences 76, 5–19, doi:https://doi.org/10.15690/vramn1528 (2021).
10 Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370, doi:10.1126/science.abd4250 (2020).
11 Farrera-Soler, L. et al. Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. PLoS One 15, e0238089, doi:10.1371/journal.pone.0238089 (2020).
12 Yi, Z. et al. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerg Microbes Infect 9, 1988-1996, doi:10.1080/22221751.2020.1815591 (2020).
13 Poh, C. M. et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun 11, 2806, doi:10.1038/s41467-020-16638-2 (2020).
14 Li, Y. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol 17, 1095-1097, doi:10.1038/s41423-020-00523-5 (2020).
15 Li, Y. et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep 34, 108915, doi:10.1016/j.celrep.2021.108915 (2021).
16 Vladimir Putin held a regular meeting with Government members, via videoconference. The Kremlin, Moscow http://en.kremlin.ru/events/president/news/64203 (2020).
17 Pichugina, T. in RIA-Novosti https://ria.ru/20210122/epivakkorona-1594051697.html (Moscow, 2021).
18 Ryzhikov, A. B. & et.al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) Russian Journal of Infection and Immunity 11 283-296., doi:https://doi.org/10.15789/2220-7619-ASB-1699 (2021).
19 Matveeva, O. The problem of selecting peptides for EpiVacCorona and a review of the article by the vaccine developers on phase I and phase II clinical trials BioMolecule (in Russian) An informative online publication about modern biology.https://biomolecula.ru/articles/problema-vybora-peptidov-dlia-epivakkorony (2021).
20 Krinitsky, A. A. Study of immunogenicity and potential protectiveness of EpiVacCorona vaccine. COVID19-PREPRINTS.MICROBE.RU, doi:https://doi.org/10.21055/preprints-3111948 (2021).
21 ClinicalTrialNCT04780035. (ed Sponsor "Vector") (March 3, 2021).
22 Mishra, S. et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine 39, 101064, doi:10.1016/j.eclinm.2021.101064 (2021).
23 Rella, S. A., Kulikova, Y. A., Dermitzakis, E. T. & Kondrashov, F. A. Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains. Sci Rep 11, 15729, doi:10.1038/s41598-021-95025-3 (2021).
24 Brown, C. M. et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 70, 1059-1062, doi:10.15585/mmwr.mm7031e2 (2021).
25 Chia, P. Y. et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect 28, 612 e611-612 e617, doi:10.1016/j.cmi.2021.11.010 (2022).
26 Bian, L. et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines, 1-9, doi:10.1080/14760584.2021.1976153 (2021).
27 Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 385, 585-594, doi:10.1056/NEJMoa2108891 (2021).
28 Harder, T. et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill 26, doi:10.2807/1560-7917.ES.2021.26.41.2100920 (2021).
29 Dolzhikova, I. V. et al. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow. medRxiv, 2021.2010.2008.21264715, doi:10.1101/2021.10.08.21264715 (2021).
30 Mullen J.L., Tsueng G. & Latif A.A., e. a. (Center for Viral Systems Biology, 2021).
31 Knorre, D., Nabiyeva, E., Garushyants, S. K., Bazykin G.A. & (2021).
32 Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, doi:10.1038/s41586-021-03944-y (2021).
33 Barchuk, A. et al. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia. medRxiv, 2022.2001.2024.22269714, doi:10.1101/2022.01.24.22269714 (2022).
34 Hansen, C. H., Michlmayr, D., Gubbels, S. M., Molbak, K. & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 397, 1204-1212, doi:10.1016/S0140-6736(21)00575-4 (2021).
35 Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410-416, doi:10.1038/s41586-021-03791-x (2021).
36 Sjaarda, C. P. et al. Distinct age-specific SARS-CoV-2 IgG decay kinetics following natural infection. medRxiv, 2021.2008.2005.21259465, doi:10.1101/2021.08.05.21259465 (2021).
37 Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331-2333, doi:10.1016/S0140-6736(21)01290-3 (2021).
38 Mwimanzi, F. et al. Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. J Infect Dis, doi:10.1093/infdis/jiac199 (2022).
39 Keshavarz, B. et al. Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Front Immunol 13, 850987, doi:10.3389/fimmu.2022.850987 (2022).
40 Grange, Z. et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. The Lancet, doi:DOI:https://doi.org/10.1016/S0140-6736(21)02316-3 (2021).
41 Nordstrom, P., Ballin, M. & Nordstrom, A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health Eur 11, 100249, doi:10.1016/j.lanepe.2021.100249 (2021).
42 Andrews, N. et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med 386, 340-350, doi:10.1056/NEJMoa2115481 (2022).
43 Pouwels, K. B. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 27, 2127-2135, doi:10.1038/s41591-021-01548-7 (2021).
44 Taquet, M., Dercon, Q. & Harrison, P. J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 103, 154-162, doi:10.1016/j.bbi.2022.04.013 (2022).
45 Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407-1416, doi:10.1016/S0140-6736(21)02183-8 (2021).
46 Goldberg, Y. et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med, doi:10.1056/NEJMoa2114228 (2021).
47 Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 375, e067873, doi:10.1136/bmj-2021-067873 (2021).
48 Tang, P. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med, doi:10.1038/s41591-021-01583-4 (2021).
49 Delbrück, M. et al. Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination. Front. Aging, doi:https://doi.org/10.3389/fragi.2022.883724 (2022).
50 Andrews, N. et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med 28, 831-837, doi:10.1038/s41591-022-01699-1 (2022).
51 https://t.me/COVID19VaccinesNews/9479.
52 https://www.gosuslugi.ru/covid-cert/. (2021).
53 https://rosstat.gov.ru/compendium/document/13284. (2021).
54 https://gogov.ru/covid-v-stats/msk. (2021).
55 https://coronavirus-monitor.info/. (2021).
56 Weinberg, G. A. & Szilagyi, P. G. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201, 1607-1610, doi:10.1086/652404 (2010).
57 Tenny, S. & Hoffman, M. R. in StatPearls (2021).
58 McHugh, M. L. The chi-square test of independence. Biochem Med (Zagreb) 23, 143-149, doi:10.11613/bm.2013.018 (2013).
59 in https://github.com/anershov/epivaccorona_effectiveness_moscow (2022).
60 Matveeva, O. & Ershov, A. Retrospective cohort study of the efficiency of Sputnik V and EpiVacCorona vaccines against infections and deaths caused by SARS-CoV-2 Delta variant in Moscow (June-July 2021), preprint in ResearchGate https://www.researchgate.net/publication/358106280_Retrospective_cohort_study_of_the_efficiency_of_Sputnik_V_and_EpiVacCorona_vaccines_against_infections_and_deaths_caused_by_SARS-CoV-2_Delta_variant_in_Moscow_June-_July_2021. (2022).